Optiscan Imaging Limited · ASX:OIL
Optiscan Imaging — Shareholder Meeting (November 2020)
18 slides from Optiscan Imaging's shareholder meeting presentation, Nov 26, 2020
Slide 1: Optiscan Imaging Ltd
Optiscan Imaging Ltd (ASX:OIL) Building A Global Medical Imaging And Diagnostics Company
Slide 2: Notice
Notice This presentation has been prepared by Optiscan Imaging Limited (OIL or the Company) as at 26 November 2020. The information in this presentation is of a general nature and does not purport to be complete. The presentation does not contain all of the information which a prospective investor m
Slide 3: Notice
Notice Not an offer or financial productadvice This presentation is not a prospectus, product disclosure statement or other offering document under Australian law (and will not be lodged with ASIC) or any other law. This presentation does not satisfy the disclosure requirements for a disclosure docu
Slide 4: Building A Global Scale Medical Imaging And Diagnostics Company
Building A Global Scale Medical Imaging And Diagnostics Company Board Total Securities on Issue Darren Lurie – CEO and Executive Chair ▪ 596,730,300 Ordinary Shares B.LLB (Hons) and B.COM (Hons) ▪ 25,600,000 unlisted options Executive Chair since May 2018. Former Group CFO and Head of Corporate Deve
Slide 5: Milestones and Share Price Movement for 2020
Milestones and Share Price Movement for 2020
Slide 6: Operating Cash Flow Summary
Operating Cash Flow Summary Net Cash Used In Operating Activities 0 -0.5 FY 2017 FY 2018 FY 2019 FY 2020 CY2021 AUD (Millions) -1 (10 mths)* -1.5 -2 -2.5 -3 -3.5 -4 Financial Years July to June (FY) Calendar Year January to December (CY) * Audited Results for January to June 2020 and unaudited resul
Slide 7: Optiscan's InVivage Clinical Device
Optiscan’s InVivage® Clinical Device ❑ Real-time “virtual biopsy“ with instantaneous, sub-cellular resolution imaging ❑ Cancer Screening and Surgical Applications ❑ Button controls on probe enabling single handed operation ❑ Lodged patent application for new InVivage® features Clinical Applications:
Slide 8: Key Steps Towards FDA 510(k) for Optiscan's InVivage
Key Steps Towards FDA 510(k) for Optiscan’s InVivage® ▪ US FDA Q-submission meeting in January 2020. ▪ Positive written and verbal feedback received from the FDA in October 2020 regarding the proposed 510(k) submission. ▪ Commencement of third-party testing required for the FDA 510(k) submission. ▪
Slide 9: OPTISCAN – Clinical Studies
OPTISCAN – Clinical Studies 150 patient Oral Cancer Study at Melbourne Dental School funded by Australian Government BioMedtech Horizons Program Oral Cancer Study at the Memorial Sloan Kettering Cancer Centre in New York. Oral Cancer Screening Study at the Australian Centre for Oral Oncology Oral Ca
Slide 10: Publications in 2020
Publications in 2020 Spp24 is associated with Fluorescence-guided Validation of the use of Poly(ADP- endocytic signalling, resection of tumors in a fluorescent PARP1 ribose)polymerase1: A lipid metabolism, and mouse models of oral inhibitor for the potential molecular discrimination of tissue cancer
Slide 11: Building Government and Association Relationships
Building Government and Association Relationships ❑ Developing Government (State and Federal) and Biotechnology Industry connections: ❑ - Global Victoria ❑ - Department of Industry ❑ - CSIRO ❑ - Invest Vic ❑ Science and Technology (Federal) ❑ - AusBiotech ❑ - Department of Jobs (VIC) ❑ - Department
Slide 12: World Lip & Oral Cavity Cancer Incidence And Mortality
World Lip & Oral Cavity Cancer Incidence And Mortality 2% 350k 177k Of all cancer New cases Total deaths Incidence 1 in 2018 1 in 2018 1 >80% 57% 2.5x Survival Survival Cost Early Diagnosis 2 Late Diagnosis 2 Early Vs Late 2 1. Bray, F., et al., Global cancer statistics 2018: GLOBOCAN estimates of i
Slide 13: Oral Cancer Market Size
Oral Cancer Market Size ❑ United States ❑ China 71 NCI Designated Cancer Centers 1 786 Specialist Stomatological Hospitals in 2018 2 900 Specialist Cancer Centers Number and Growth of Stomatological (Dental) 6,146 Total US Hospitals Specialist Hospitals in China from 2011 to 2018 900 9,000 Oral and
Slide 14: Breast Cancer - Most Common Cancer in Women
Breast Cancer - Most Common Cancer in Women 2.1 15% 8.5% Million 2.1 million new cases of 15% of all 8.5% of all new cancer breast cancer predicted in new cancer cases in the cases in China are breast 2018 (globally) 1 US are breast cancer 2 cancer 3 • 20-30% of lumpectomy patients currently require
Slide 15: CONVIVO – Carl Zeiss Meditec (CZM) Co-operation
CONVIVO® – Carl Zeiss Meditec (CZM) Co-operation ❑ FDA 510(k) clearance, CE Mark and TGA approval obtained ❑ Final Milestone payment received and movement to production phase ❑ Trials using CONVIVO in brain tumor resection are underway in Europe and United States and proposed in Australia for 2021 ❑
Slide 16: Distribution Model for the Preclinical Device (FIVE2)
Distribution Model for the Preclinical Device (FIVE2) China Asia Pacific North America China Korea Japan Singapore ❑ South and West China Distributor: ❑ Appointment of Asia Pacific ❑ Appointment of Advanced Guangzhou Yunxing Distribution Manager Microscopy Consultancy Services Inc as North America D
Slide 17: Outlook for 2021
Outlook for 2021 ▪ Commencement of 150 patient Oral Cancer Study at the Melbourne Dental School and Stage 3 of breast cancer trial at Royal Melbourne Hospital ▪ FDA 510(k) Oral imaging submission planned for first half of CY2021 ▪ Develop distribution strategy for InVivage® into United States market
Slide 18: Darren Lurie CEO and Executive Chair Optiscan Imaging Limited
Darren Lurie CEO and Executive Chair Optiscan Imaging Limited (ASX:OIL) www.optiscan.com
Optiscan Imaging — Shareholder Meeting (November 2020) on 6ix